Study finds high tumor mutation burden predicts immunotherapy response in some, but not all, cancers

(University of Texas M. D. Anderson Cancer Center) A high rate of genetic mutations within a tumor, known as high tumor mutation burden, was only useful for predicting immunotherapy responses in a subset of cancer types, suggesting that this may not reliably be used as a universal biomarker.